A European firm that procures pharmaceutical products for comparator trials and named-patient programmes for drug companies and clinical research organisations worldwide has set up a US office.
Pharmarama is headquartered in London, UK, and also has offices in Germany. It has launched a corporate website to coincide with the establishment of its sales and marketing office in Boston, USA.
The company was founded in 2006 by pharmacist Ben Rabin as the US affiliate of UK-based BR Pharma Ltd, which first gained recognition for obtaining regulatory permission to import the stimulant Ritalin SR® (methylphenidate) into the UK.
Pharmarama, a licensed wholesaler and importer of licensed and unlicensed medicines, collaborates with BR Pharma as a single point of contact for sourcing, repacking, blinding and distribution of comparator drugs worldwide.
Tammy Bishop, Pharmarama’s vice-president of US business development, said the website aimed to provide clients and prospects with easily accessible information and serve as an interactive communication medium, keeping clients up to date on latest developments in the field and providing useful links to industry resources.
The firm’s named-patient programmes aim to allow for the supply and use of unlicensed medicines under strictly limited conditions to meet the special needs of a particular patient where a licensed equivalent does not exist.
Named-patient medicines include those that are not yet licensed in a territory, as well as investigational drugs awaiting approval. Pharmarama works with drug firms to establish formally structured named-patient programmes in the pre-launch phase of a medicine’s lifecycle.
Comparator drugs are used in clinical trials to compare therapies under review with current therapies commercially available in the market. Ms Bishop said some 20% of clinical pharmaceutical studies globally used comparator products.